AMG 714 + Placebo
Phase 2Completed 1 views this week 0 watching💤 Quiet
Interest: 35/100
35
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Type II Refractory Celiac Disease (RCD-II)
Conditions
Type II Refractory Celiac Disease (RCD-II), In-situ Small Bowel T-cell Lymphoma
Trial Timeline
Apr 13, 2016 → May 2, 2017
NCT ID
NCT02633020About AMG 714 + Placebo
AMG 714 + Placebo is a phase 2 stage product being developed by Amgen for Type II Refractory Celiac Disease (RCD-II). The current trial status is completed. This product is registered under clinical trial identifier NCT02633020. Target conditions include Type II Refractory Celiac Disease (RCD-II), In-situ Small Bowel T-cell Lymphoma.
What happened to similar drugs?
20 of 20 similar drugs in Type II Refractory Celiac Disease (RCD-II) were approved
Approved (20) Terminated (0) Active (0)
Hype Score Breakdown
Clinical
12
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (3)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04338581 | Phase 2 | Completed |
| NCT02637141 | Phase 2 | Completed |
| NCT02633020 | Phase 2 | Completed |
Competing Products
20 competing products in Type II Refractory Celiac Disease (RCD-II)